Regeneron links 2026 CEO, CSO PSU awards to FDA and revenue targets through 2035
REGN•Regeneron set 10-year performance stock unit awards for its CEO and CSO, tying payouts to FDA filings and approvals through 2034-2035 and new-product revenue targets in 2032-2035. Revenue awards range from 250,000 PSUs at $10 billion to 1.8 million at $30 billion, with total award caps of 2.7 million for the CEO and 2.9 million for the CSO.
1. Award performance targets
The awards have a 10-year performance window beginning Jan. 1, 2026, with earnouts tied to FDA filing and approval activity through 2034-2035 and new-product revenue in 2032-2035. Revenue-based awards use linear interpolation between 250,000 PSUs at $10 billion and 1.8 million at $30 billion; a relative total shareholder return modifier of up to plus or minus 20% versus the Nasdaq Biotechnology Index applies, with an absolute-TSR floor blocking upward adjustments.
